Transforming The Management Of Critical Bleeding and Clotting

HemoSonics is bringing to market a next-generation point-of-care diagnostic platform, the Quantra, that provides actionable information to guide the management of critical bleeding and clotting.

Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted selection and dosing of blood products in critical settings. We seek to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely and accurate information on coagulation status at the point of care, enabling clinicians to rapidly choose the right treatment, dramatically improving outcomes and lowering treatment costs.

Our Products

The Quantra™ is a rapid, easy-to-use, point-of-care diagnostic platform that fully characterizes and guides the management of critical bleeding.
Learn more.

Our Technology

Our patented SEER sonorheometry technology quantifies coagulation by measuring the evolving stiffness of clotting blood.
Learn more.

Our Leadership

Our team has a proven track record of successfully developing and bringing to market innovative medical devices.
Learn more.

Blood cells

Studies show that use of comprehensive point-of-care coagulation testing in surgical settings leads to:

Improved clinical outcomes

  • Fewer transfusions
  • Fewer complications

Reduced cost of care

  • Reduced blood product utilization
  • Shorter inpatient stays


Anesthesia & Analgesia Profiles Quantra’s SEER Technology in Article of the Month and Podcast

Charlottesville, VA  – December 7, 2016 – The editorial staff of Anesthesia & Analgesia has chosen the article “A Novel Device for the Evaluation of Hemostatic Function in Critical Care Settings,” which details the Quantra™ Hemostasis Analyzer, as its Article of the Month featured on the journal’s home page. The article introduces the Quantra analyzer and the Surgical Cartridge and presents the results of analytical performance testing using a research version of the Quantra. These results demonstrate the ability of the Quantra and the Surgical Cartridge to rapidly and comprehensively characterize the key functional components of hemostasis. In addition, has conducted a podcast with Dr. Francesco Viola, Founder and Chief Scientific Officer of HemoSonics, about the article and the Quantra Hemostasis Analyzer. The interview can be found at: Contact Megan Shaw HemoSonics 434.260.0682... read more

Abstract on SEER Technology to be Presented at PGA

Charlottesville, VA – December 6, 2016– HemoSonics today announced the upcoming presentation of data at the Post Graduate Assembly in Anesthesiology (PGA) Meeting demonstrating the potential of the Quantra™ Hemostasis Analyzer to aid clinicians in identifying the need for transfusion of allogeneic blood products in major spine surgery. The conference will be held in New York, NY December 9 – 13, 2016. The reported study was conducted at the University of Virginia in Charlottesville, VA and compared results obtained with a research version of the Quantra™ Hemostasis Analyzer to equivalent rotational thromboelastometery (ROTEM™) and conventional laboratory parameters. The abstract “Predicting Cryoprecipitate and Platelet Transfusion During Major Spine Surgery with SEER Sonorheometry versus Rotational Thromboelastometry” authored by Dr. Bhiken Naik, Dr. Marcel Durieux, and Dr. Edward Nemergut, all faculty in the Department of Anesthesiology at the University of Virginia, showed significant differences in the Quantra measurements of Clot Stiffness, Platelet Contribution and Fibrinogen Contribution between the patients that received a transfusion and those that did not. The area under the Receiver Operative Curves (ROC), a measure of the performance of a diagnostic test, for Fibrinogen Contribution versus cryoprecipitate transfusion, Clot Stiffness versus cryoprecipitate-platelet transfusion, and Platelet Contribution versus platelet transfusions were 0.8, 0.79, and 0.8, respectively. These data indicate that the Quantra and SEER Sonorheometry may provide clinically relevant measurements that could be utilized to aid in the management of perioperative bleeding. Abstract Details Title: Predicting Cryoprecipitate and Platelet Transfusion During Major Spine Surgery with SEER Sonorheometry versus Rotational Thromboelastometry Authors: Naik, BI, Durieux, ME, Nemergut, EC Date: December 11, 2016, 9:30am Board:  P-9092 Contact Megan Shaw HemoSonics 434.260.0682... read more

HemoSonics’ Groundbreaking System for the Management of Critical Bleeding Presented in Four Articles in Anesthesia & Analgesia

Clinical Studies Showed Rapid and Comprehensive Measurement of Coagulation at the Point-of-Care Charlottesville, VA, September 20, 2016 – HemoSonics announced today the publication of four journal articles, accompanied by an editorial, in Anesthesia & Analgesia describing the first clinical experiences with the QuantraTM Hemostasis Analyzer, a groundbreaking system designed to transform and improve the management of critical bleeding. These papers introduce the device and describe the results of multi-center clinical studies involving more than 150 cardiac and spine surgery patients. The leading editorial highlights Quantra’s novel SEER Sonorheometry technology, which may provide significant advantages over existing systems. “The Quantra is a major leap forward in viscoelastic testing, as current hemostasis testing is limited by long result times and incomplete parameter measures,” said Dr. Bruce Spiess, Professor and Associate Chief for Research within the Department of Anesthesiology at the University of Florida and lead author of one of the papers. “These studies demonstrate that the Quantra provides clot time and clot stiffness results that correlate with existing technologies. In addition, the device delivers extremely important information through its Fibrinogen Contribution and Platelet Contribution measures that are not currently available in a rapid time frame. With the Quantra, we have a tool to help rapidly and accurately determine the cause of critical bleeding, enabling precise treatment and reducing unnecessary blood transfusions.” The Quantra and its Surgical Cartridge, the first in a series of test cartridges, were designed to facilitate quick and precise treatment of critical bleeding. These studies demonstrate the ability of the Quantra to monitor coagulation at the point of care in critical care settings and generate comprehensive results in... read more

Introduction to Quantra™ Published in Anesthesia and Analgesia

Charlottesville, VA – June 6, 2016 – HemoSonics today announced that a paper introducing its novel QuantraTM Hemostasis Analyzer was published online in Anesthesia and Analgesia. The paper, A Novel Device for the Evaluation of Hemostatic Function in Critical Care Settings, introduces the Quantra and its initial Surgical Cartridge, which is intended for monitoring coagulation during and after major surgical procedures with potential applications in other critical care settings. The Quantra system was designed to address the market gap for a rapid, comprehensive, easy-to-use, near-patient coagulation analyzer. The paper describes key findings from comparative studies using a research use only (RUO) version of the Quantra System. The Quantra reliably characterized coagulation factor function, and quantified functional fibrinogen, platelet function, and overall clot stiffness as well as the presence of residual heparin anticoagulation. Dysfunctions of these coagulation components are the primary sources of bleeding during and after major surgery. In addition, all Quantra results were obtained within 15 minutes of test initiation, an extremely rapid response for such comprehensive information. The study demonstrated highly reproducible results, with coefficients of variation for each output parameter ranging from 2.5% to 8.8%. In addition, the Quantra displayed a wide dynamic range for measuring clot stiffness, enabling measurement of very soft clots that are often associated with clinical bleeding. Furthermore, Quantra results correlated strongly with existing laboratory tests such as Clauss Fibrinogen. “These findings demonstrate that the Quantra provides a rapid and comprehensive view of a patient’s coagulation status, something currently unavailable today,” said Francesco Viola, Chief Scientific Officer of HemoSonics and lead author on the paper. “These findings suggest that the Quantra and the... read more